Microbiota-targeted therapies: An ecological perspective

Science Translational Medicine

Volumn 4, Issue 137, 2012, Pages

  Lemon, Katherine P ^a,b   Armitage, Gary C ^c   Relman, David A ^d,e   Fischbach, Michael A ^c,f  

^a FORSYTH INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HOST PATHOGEN INTERACTION; HUMAN; MICROBIAL COMMUNITY; MICROBIOME; MICROFLORA; MOLECULAR THERAPY; NONHUMAN; OUTCOME ASSESSMENT; POPULATION DYNAMICS; PRIORITY JOURNAL; REVIEW; SECONDARY INFECTION; SPECIES COMPOSITION; SPECIES DIFFERENCE; SPECIES DIVERSITY; SPECIES INVASION; STAPHYLOCOCCUS INFECTION; SYMBIONT; THERAPY EFFECT; VACCINATION; DRUG EFFECT; METAGENOME; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; HUMANS; METAGENOME; PROBIOTICS;

EID: 84861972212     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004183     Document Type: Review

References (65)

1. E. Costello, K. Stagaman, L. Dethlefsen, B. J. M. Bohannon, D. A. Relman, The application of ecological theory towards an understanding of the human microbiome. Science, 336, 1255-1262 (2012).
2. C. P. Tamboli, C. Neut, P. Desreumaux, J. F. Colombel, Dysbiosis in inflammatory bowel disease. Gut 53, 1-4 (2004).
3. R. Kolter, A visit to the paediatrician in the not-so-distant future. Environ. Microbiol. Rep. 1, 12-16 (2009).
4. L. J. Lesko, A. J. Atkinson Jr., Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41, 347-366 (2001).
5. M. Mshvildadze, J. Neu, J. Shuster, D. Theriaque, N. Li, V. Mai, Intestinal microbial ecology in premature infants assessed with non-culture-based techniques. J. Pediatr. 156, 20- 25 (2010).
6. J. Neu, W. A. Walker, Necrotizing enterocolitis. N. Engl. J. Med. 364, 255-264 (2011).
7. Y. Wang, J. D. Hoenig, K. J. Malin, S. Qamar, E. O. Petrof, J. Sun, D. A. Antonopoulos, E. B. Chang, E. C. Claud, 16S rRNA gene-based analysis of fecal microbiota from preterm infants with and without necrotizing enterocolitis. ISME J. 3, 944- 954 (2009).
8. J. Ravel, P. Gajer, Z. Abdo, G. M. Schneider, S. S. Koenig, S. L. McCulle, S. Karlebach, R. Gorle, J. Russell, C. O. Tacket, R. M. Brotman, C. C. Davis, K. Ault, L. Peralta, L. J. Forney, Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. U.S.A. 108 (Suppl. 1), 4680- 4687 (2011).
9. V. Klepac-Ceraj, K. P. Lemon, T. R. Martin, M. Allgaier, S. W. Kembel, A. A. Knapp, S. Lory, E. L. Brodie, S. V. Lynch, B. J. Bohannan, J. L. Green, B. A. Maurer, R. Kolter, Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ. Microbiol. 12, 1293-1303 (2010).
10. H. Sokol, B. Pigneur, L. Watterlot, O. Lakhdari, L. G. Bermúdez-Humarán, J. J. Gratadoux, S. Blugeon, C. Bridonneau, J. P. Furet, G. Corthier, C. Grangette, N. Vasquez, P. Pochart, G. Trugnan, G. Thomas, H. M. Blottière, J. Doré, P. Marteau, P. Seksik, P. Langella, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A. 105, 16731-16736 (2008).
11. B. Willing, J. Halfvarson, J. Dicksved, M. Rosenquist, G. Järnerot, L. Engstrand, C. Tysk, J. K. Jansson, Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn 's disease. Inflamm. Bowel Dis. 15, 653-660 (2009).
12. F. Hayashi, M. Okada, Y. Soda, K. Miura, K. Kozai, Subgingival distribution of Campylobacter rectus and Tannerella forsythensis in healthy children with primary dentition. Arch. Oral Biol. 51, 10- 14 (2006).
13. J. Li, E. J. Helmerhorst, C. W. Leone, R. F. Troxler, T. Yaskell, A. D. Haffajee, S. S. Socransky, F. G. Oppenheim, Identification of early microbial colonizers in human dental biofilm. J. Appl. Microbiol. 97, 1311-1318 (2004).
14. A. C. Tanner, P. M. Milgrom, R. Kent Jr., S. A. Mokeem, R. C. Page, C. A. Riedy, P. Weinstein, J. Bruss, The microbiota of young children from tooth and tongue samples. J. Dent. Res. 81, 53-57 (2002).
15. M. Wilson, D. Lopatin, G. Osborne, J. B. Kieser, Prevalence of Treponema denticola and Porphyromonas gingivalis in plaque from periodontally-healthy and periodontally-diseased sites. J. Med. Microbiol. 38, 406-410 (1993).
16. E. Gough, H. Shaikh, A. R. Manges, Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53, 994-1002 (2011).
17. C. J. Robinson, B. J. Bohannan, V. B. Young, From structure to function: The ecology of host-associated microbial communities. Microbiol. Mol. Biol. Rev. 74, 453 -476 (2010).
18. Centers for Disease Control and Prevention (CDC), Progress toward elimination of Haemophilus influenzae type b disease among infants and children-United States, 1987-1995. MMWR Morb. Mortal. Wkly. Rep. 45, 901-906 (1996).
19. W. G. Adams, K. A. Deaver, S. L. Cochi, B. D. Plikaytis, E. R. Zell, C. V. Broome, J. D. Wenger, Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269, 221-226 (1993).
20. J. C. Mohle-Boetani, G. Ajello, E. Breneman, K. A. Deaver, C. Harvey, B. D. Plikaytis, M. M. Farley, D. S. Stephens, J. D. Wenger, Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J. 12, 589-593 (1993).
21. A. K. Takala, J. Eskola, M. Leinonen, H. Käyhty, A. Nissinen, E. Pekkanen, P. H. Mäkelä, Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 164, 982-986 (1991).
22. Centers for Disease Control and Prevention (CDC), Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - Eight states, 1998-2005. MMWR Morb. Mortal. Wkly. Rep. 57, 144-148 (2008).
23. C. G. Whitney, M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, A. Schuchat; Active Bacterial Core Surveillance of the Emerging Infections Program Network, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003).
24. L. Dethlefsen, M. McFall-Ngai, D. A. Relman, An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449, 811-818 (2007).
25. G. Regev-Yochay, D. Bogaert, R. Malley, P. W. M. Hermans, R. H. Veenhoven, E. A. M. Sanders, M. Lipsitch, E. Rubinstein, Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children? Clin. Infect. Dis. 47, 289-291 (2008).
26. R. Blumberg, F. Powrie, Microbiota, disease, and back again to health: A metastable journey. Sci. Transl. Med. 4, 137rv7 (2012).
27. L. V. Hooper, D. R. Littman, A. J. Macpherson, Interactions between the microbiota and the immune system. Science 336, 1268-1273 (2012).
28. M. Blaser, Antibiotic overuse: Stop the killing of beneficial bacteria. Nature 476, 393 -394 (2011).
29. L. Dethlefsen, D. A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U.S.A. 108, (Suppl. 1), 4554-4561 (2011).
30. A. Spinillo, E. Capuzzo, S. Acciano, A. De Santolo, F. Zara, Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am. J. Obstet. Gynecol. 180, 14-17 (1999).
31. C. P. Kelly, J. T. LaMont, Clostridium difficile - More difficult than ever. N. Engl. J. Med. 359, 1932-1940 (2008).
32. Centers for Disease Prevention (CDC), Vital signs: Preventing Clostridium difficile infections. MMWR. Morb. Mortal. Wkly. Rep. 61, 157-162 (2012).
33. E. Mattila, R. Uusitalo-Seppälä, M. Wuorela, L. Lehtola, H. Nurmi, M. Ristikankare, V. Moilanen, K. Salminen, M. Seppälä, P. S. Mattila, V. J. Anttila, P. Arkkila, Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142, 490-496 (2012).
34. D. W. Thomas, F. R. Greer; American Academy of Pediatrics Committee on Nutrition; American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition, Probiotics and prebiotics in pediatrics. Pediatrics 126, 1217-1231 (2010).
35. B. C. Johnston, J. Z. Goldenberg, P. O. Vandvik, X. Sun, G. H. Guyatt, Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst. Rev. 11, CD004827 (2011).
36. S. H. Cohen, D. N. Gerding, S. Johnson, C. P. Kelly, V. G. Loo, L. C. McDonald, J. Pepin, M. H. Wilcox; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America, Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010).
37. J. W. Chow, V. L. Yu, Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch. Intern. Med. 149, 1258-1262 (1989).
38. S. A. Fritz, P. G. Hogan, G. Hayek, K. A. Eisenstein, M. Rodriguez, E. K. Epplin, J. Garbutt, V. J. Fraser, Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: A randomized trial. Clin. Infect. Dis. 54, 743-751 (2012).
39. R. E. Newman, E. B. Hedican, J. C. Herigon, D. D. Williams, A. R. Williams, J. G. Newland, Impact of a guideline on management of children hospitalized with community-acquired pneumonia. Pediatrics 129, e597-e604 (2012).
40. J. S. Bradley, C. L. Byington, S. S. Shah, B. Alverson, E. R. Carter, C. Harrison, S. L. Kaplan, S. E. Mace, G. H. McCracken Jr., M. R. Moore, S. D. St Peter, J. A. Stockwell, J. T. Swanson; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, Executive summary: The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 53, 617-630 (2011).
41. A. E. Little, C. J. Robinson, S. B. Peterson, K. F. Raffa, J. Handelsman, Rules of engagement: Interspecies interactions that regulate microbial communities. Annu. Rev. Microbiol. 62, 375-401 (2008).
42. C. I. Liu, G. Y. Liu, Y. Song, F. Yin, M. E. Hensler, W. Y. Jeng, V. Nizet, A. H. Wang, E. Oldfield, A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319, 1391-1394 (2008).
43. D. J. Haydon, N. R. Stokes, R. Ure, G. Galbraith, J. M. Bennett, D. R. Brown, P. J. Baker, V. V. Barynin, D. W. Rice, S. E. Sedelnikova, J. R. Heal, J. M. Sheridan, S. T. Aiwale, P. K. Chauhan, A. Srivastava, A. Taneja, I. Collins, J. Errington, L. G. Czaplewski, An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321, 1673-1675 (2008).
44. D. López, H. Vlamakis, R. Kolter, Biofilms. Cold Spring Harb. Perspect. Biol. 2, a000398 (2010).
45. R. O. Darouiche, Treatment of infections associated with surgical implants. N. Engl. J. Med. 350, 1422-1429 (2004).
46. S. Furukawa, S. L. Kuchma, G. A. O' Toole, Keeping their options open: Acute versus persistent infections. J. Bacteriol. 188, 1211- 1217 (2006).
47. I. Kolodkin-Gal, D. Romero, S. Cao, J. Clardy, R. Kolter, R. Losick, D-Amino acids trigger biofilm disassembly. Science 328, 627-629 (2010).
48. P. S. Stewart, J. W. Costerton, Antibiotic resistance of bacteria in biofilms. Lancet 358, 135 -138 (2001).
49. E. Denou, R. D. Pridmore, B. Berger, J. M. Panoff, F. Arigoni, H. Brüssow, Identification of genes associated with the long-gut-persistence phenotype of the probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and transcriptome analysis. J. Bacteriol. 190, 3161- 3168 (2008).
50. E. Holmes, J. Kinross, G. R. Gibson, R. Burcelin, W. Jia, S. Pettersson, J. K. Nicholson, Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl. Med. 4, 137rv6 (2012).
51. J. Nicholson, E. Holmes, J. Kinross, R. Burcelin, G. Gibson, W. Jia, S. Pettersson, Host-gut microbiota metabolic interactions. Science 336, 1262-1267 (2012).
52. A. R. Hughes, B. D. Inouye, M. T. Johnson, N. Underwood, M. Vellend, Ecological consequences of genetic diversity. Ecol. Lett. 11, 609-623 (2008).
53. J. J. Faith, N. P. McNulty, F. E. Rey, J. I. Gordon, Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 333, 101-104 (2011).
54. M. Arumugam, J. Raes, E. Pelletier, D. Le Paslier, T. Yamada, D. R. Mende, G. R. Fernandes, J. Tap, T. Bruls, J. M. Batto, M. Bertalan, N. Borruel, F. Casellas, L. Fernandez, L. Gautier, T. Hansen, M. Hattori, T. Hayashi, M. Kleerebezem, K. Kurokawa, M. Leclerc, F. Levenez, C. Manichanh, H. B. Nielsen, T. Nielsen, N. Pons, J. Poulain, J. Qin, T. Sicheritz-Ponten, S. Tims, D. Torrents, E. Ugarte, E. G. Zoetendal, J.Wang, F. Guarner, O. Pedersen, W. M. de Vos, S. Brunak, J. Doré; MetaHIT Consortium, M. Antolín, F. Artiguenave, H. M. Blottiere, M. Almeida, C. Brechot, C. Cara, C. Chervaux, A. Cultrone, C. Delorme, G. Denariaz, R. Dervyn, K. U. Foerstner, C. Friss, M. van de Guchte, E. Guedon, F. Haimet, W. Huber, J. van Hylckama-Vlieg, A. Jamet, C. Juste, G. Kaci, J. Knol, O. Lakhdari, S. Layec, K. Le Roux, E.Maguin, A. Mérieux, R. Melo Minardi, C. M' Rini, J. Muller, R. Oozeer, J. Parkhill, P. Renault, M. Rescigno, N. Sanchez, S. Sunagawa, A. Torrejon, K. Turner, G. Vandemeulebrouck, E. Varela, Y. Winogradsky, G. Zeller, J. Weissenbach, S. D. Ehrlich, P. Bork, Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011).
55. H. H. Kong, J. Oh, C. Deming, S. Conlan, E. A. Grice, M. A. Beatson, E. Nomicos, E. C. Polley, H. D. Komarow; NISC Comparative Sequence Program, P. R. Murray, M. L. Turner, J. A. Segre, Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 22, 850-859 (2012).
56. R. T. Zahradnik, I. Magnusson, C. Walker, E. McDonell, C. H. Hillman, J. D. Hillman, Preliminary assessment of safety and effectiveness in humans of ProBiora3, a probiotic mouthwash. J. Appl. Microbiol. 107, 682- 690 (2009).
57. F. Shanahan, Probiotics in perspective. Gastroenterology 139, 1808-1812 (2010).
58. G. Deshpande, S. Rao, S. Patole, M. Bulsara, Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 125, 921-930 (2010).
59. D. Sur, B. Manna, S. K. Niyogi, T. Ramamurthy, A. Palit, K. Nomoto, T. Takahashi, T. Shima, H. Tsuji, T. Kurakawa, Y. Takeda, G. B. Nair, S. K. Bhattacharya, Role of probiotic in preventing acute diarrhoea in children: A community-based, randomized, double-blind placebo-controlled field trial in an urban slum. Epidemiol. Infect. 139, 919-926 (2011).
60. X. W. Gao, M. Mubasher, C. Y. Fang, C. Reifer, L. E. Miller, Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am. J. Gastroenterol. 105, 1636-1641 (2010).
61. S. Hempel, S. J. Newberry, A. R. Maher, Z. Wang, J. N. V. Miles, R. Shanman, B. Johnsen, P. G. Shekelle, Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and meta-analysis. JAMA 307, 1959-1969 (2012).
62. K. Isaacs, H. Herfarth, Role of probiotic therapy in IBD. Inflamm. Bowel. Dis. 14, 1597-1605 (2008).
63. D. M. Brenner, M. J. Moeller, W. D. Chey, P. S. Schoenfeld, The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am. J. Gastroenterol. 104, 1033-1049 (2009).
64. P. A. Jänne, N. Gray, J. Settleman, Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709-723 (2009).
65. N. P. McNulty, T. Yatsunenko, A. Hsiao, J. J. Faith, B. D. Muegge, A. L. Goodman, B. Henrissat, R. Oozeer, S. Cools-Portier, G. Gobert, C. Chervaux, D. Knights, C. A. Lozupone, R. Knight, A. E. Duncan, J. R. Bain, M. J. Muehlbauer, C. B. Newgard, A. C. Heath, J. I. Gordon, The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci. Transl. Med. 3, 106ra106 (2011).